Armata Pharmaceuticals, Inc. (ARMP) Financial Ratios
32 years of historical data (1993–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 2.99
30Y Low0.4·High132.5
ROE
↓
N/A
—
5yr avg: -949.2%
30Y Low-332%·High-6%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ARMP Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Armata Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $331M | $67M | $117M | $43M | $132M | $49M | $26M | $4M | $6M | $4M | $22M |
| Enterprise Value | $449M | $184M | $224M | $76M | $160M | $52M | $23M | $-4226160 | $1M | $-579060 | $12M |
| P/E Ratio → | -17.49 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 64.06 | 12.93 | 25.81 | 7.72 | 29.52 | 59.53 | — | — | 56.10 | 16.65 | 45.34 |
| P/B Ratio | — | — | — | 1.18 | 5.20 | 2.60 | 1.78 | 0.46 | 0.83 | 0.45 | 1.69 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ARMP EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 35.59 | 49.40 | 13.89 | 35.72 | 63.79 | — | — | 11.47 | -2.23 | 25.61 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
ARMP Profitability
Margins and return-on-capital ratios measuring operating efficiency
Armata Pharmaceuticals, Inc. earns an operating margin of -820.2%. Operating margins have compressed from -670.8% to -820.2% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -565.4% | -565.4% | 78.5% | -535.7% | -347.4% | -1655.0% | — | — | -225.2% | -41.9% | 100.0% |
| Operating Margin | -820.2% | -820.2% | -902.8% | -670.8% | -532.5% | -2623.0% | — | — | -14048.7% | -8991.5% | -2153.1% |
| Net Profit Margin | -365.6% | -365.6% | -1524.5% | -670.2% | -517.5% | -2695.1% | — | — | -11163.5% | -7245.4% | -108.6% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -3439.4% | -120.1% | -104.6% | -132.6% | -168.9% | -149.5% | -147.1% | -167.9% | -6.4% |
| ROA | -20.5% | -20.5% | -67.0% | -41.6% | -42.4% | -68.3% | -104.3% | -105.2% | -87.5% | -75.8% | -1.7% |
| ROIC | -44.2% | -44.2% | -42.4% | -45.0% | -47.4% | -95.9% | -243.9% | -644.2% | -326.9% | -429.8% | -7670.3% |
| ROCE | -70.7% | -70.7% | -49.6% | -49.9% | -48.7% | -80.9% | -127.7% | -135.5% | -135.9% | -106.9% | -36.6% |
ARMP Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $117M ($127M total debt minus $9M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 1.35 | 1.50 | 0.70 | 0.20 | — | — | 0.08 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | 0.94 | 1.09 | 0.19 | -0.22 | -0.96 | -0.66 | -0.50 | -0.74 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -3.95 | -3.95 | -15.57 | -1274.00 | -372.22 | -34.37 | -20.50 | — | — | — | — |
ARMP Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.23x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 1.09x to 0.23x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.23 | 0.23 | 1.16 | 1.09 | 3.11 | 1.62 | 1.36 | 3.27 | 2.74 | 1.78 | 4.20 |
| Quick Ratio | 0.23 | 0.23 | 1.16 | 1.09 | 3.11 | 1.62 | 1.36 | 3.27 | 2.74 | 1.95 | 4.20 |
| Cash Ratio | 0.19 | 0.19 | 0.82 | 0.60 | 2.14 | 1.44 | 1.24 | 3.17 | 2.61 | 1.60 | 3.93 |
| Asset Turnover | — | 0.06 | 0.05 | 0.05 | 0.06 | 0.02 | — | — | 0.01 | 0.01 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 52.49 | 271.03 | 128.29 | 243.85 | 248.80 | — | — | — | 35.10 | 96.05 |
ARMP Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Armata Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | 1.8% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.8% | 0.0% |
| Shares Outstanding | — | $36M | $36M | $34M | $24M | $16M | $8M | $1M | $456244 | $70275 | $38651 |
Peer Comparison
Compare ARMP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ARMPYou | $331M | -17.5 | — | — | -565.4% | -820.2% | — | -44.2% | — |
 PHGE | $1B | -0.0 | — | — | — | — | -316.9% | -444.8% | — |
 LSTA | $29M | -1.7 | — | — | 14.1% | -10711.2% | -75.5% | -229.7% | — |
 SIGA | $339M | 14.3 | 7.6 | 7.0 | 68.6% | 25.1% | 11.2% | 33.7% | 0.0 |
 ACXP | $5M | -0.4 | — | — | — | — | -302.4% | — | — |
 INNV | $1B | -36.7 | — | 41.2 | 68.5% | -3.5% | -10.8% | -6.8% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 ADMA | $2B | 14.1 | 10.1 | 73.1 | 57.4% | 37.5% | 35.6% | 36.0% | 0.4 |
 ICLR | $10B | 13.1 | 7.9 | 8.5 | 29.4% | 13.3% | 8.4% | 6.5% | 2.3 |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 29 years · Updated daily
See ARMP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARMP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARMP vs PHGE
Side-by-side business, growth, and profitability comparison vs BiomX Inc..
Start ComparisonARMP — Frequently Asked Questions
Quick answers to the most common questions about buying ARMP stock.
What is Armata Pharmaceuticals, Inc.'s P/E ratio?
Armata Pharmaceuticals, Inc.'s current P/E ratio is -17.5x. This places it at the 50th percentile of its historical range.
Is ARMP stock overvalued?
Based on historical data, Armata Pharmaceuticals, Inc. is trading at a P/E of -17.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Armata Pharmaceuticals, Inc.'s profit margins?
Armata Pharmaceuticals, Inc. has -565.4% gross margin and -820.2% operating margin.